With nearly 40 years of experience in meeting the needs of the biotech and pharma industry, Bioneer has established a proven track record for delivering competitive and on-time quality solutions to companies, large as well as small.
Our research strategy addresses novel solutions for drug discovery and development that fulfil the needs of companies, research institutes and health care.
We have extensive experience working with all aspects of in vitro modelling, with focus on the following areas: CNS, Cancer, Gene Editing, Immunology and Gastro-Intestinal.
We have for decades developed and produced recombinant proteins, and developed formulation technology and principles for both small molecules and biologics.
We actively seek strategic collaboration with companies and academic institutions to complement and enhance the current applied research and service knowhow.
We have extensive experience working with all aspects of In Vitro modelling.
We have for decades developed and produced recombinant proteins, and developed formulation technology and principles for both small molecules and biologics.
We actively seek strategic collaboration opportunities with companies and academic institutions to complement and enhance the current applied research and service knowhow.
Discover and read our latest news.
Kirsten Drejer passes on the baton to Karin Garre as the new Chairperson of the Board of Directors at Bioneer
At the general assembly on March 22, 2024, Bioneers saw [...]
Eurostars Grant of 2.3 Million EUR awarded to Readily3D, CelVivo, Bioneer, SDU, and EPFL: 3D cell-based assays
Eurostars Grant of 2.3 Million EUR awarded to Readily3D, CelVivo, [...]